Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06964958 · ClinicalTrials.gov registry record · Phase 2

177LuPSMA in Renal Cell Carcinoma

A Phase 2 study of Renal Cell Carcinoma and Kidney Cancer, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
Phase 2
Development phase
24
Enrollment target
2
Study locations

NCT06964958 is a Phase 2 study of Renal Cell Carcinoma and Kidney Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 24 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06964958, a Phase 2 study of Renal Cell Carcinoma and Kidney Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
24 participants
Enrollment target
2
Study locations

Study Summary

This study aims to evaluate the efficacy and safety of 177Lu-PSMA-617 as a systemic therapy in patients with PSMA-positive advanced clear cell renal cell carcinoma (ccRCC). The name of the study drug involved in this research study is: -177Lu-PSMA-617 (a type of radioligand therapy)

Conditions Studied

Renal Cell Carcinoma Kidney Cancer Advanced Clear Cell Renal Cell Carcinoma

Interventions

  • DRUG 177Lu-PSMA-617

Study Locations (2)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-07-31
Est. Completion 2028-12-01
Phase Phase 2

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06964958

The ClinicalTrials.gov registry entry for NCT06964958 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (90% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which 177Lu-PSMA-617 is the first listed.

NCT06964958 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06964958 about?

NCT06964958 is a clinical study titled "177LuPSMA in Renal Cell Carcinoma". This study aims to evaluate the efficacy and safety of 177Lu-PSMA-617 as a systemic therapy in patients with PSMA-positive advanced clear cell renal cell carcinoma (ccRCC). The name of the study drug involved in this research study is: -177Lu-PSMA-617 (a type of radioligand therapy)

What is the current status of trial NCT06964958?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2025-07-31. Estimated completion is 2028-12-01.

What conditions does trial NCT06964958 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma, Kidney Cancer, Advanced Clear Cell Renal Cell Carcinoma.

What interventions are being tested in trial NCT06964958?

The interventions under investigation include: 177Lu-PSMA-617 (DRUG).

Who is sponsoring clinical trial NCT06964958?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06964958 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

Kidney Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.